Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII
Diana Crivellari(Centro di Riferimento Oncologico), Monica Castiglione‐Gertsch(University of Geneva), Andrea Veronesi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Christoph Hürny(International Breast Cancer Study Group), Edda Simoncini(International Breast Cancer Study Group), Richard D. Gelber(Harvard University), Jurij Lindtner(International Breast Cancer Study Group), Beat Thürlimann(University of St.Gallen), John Forbes(University of Limerick), John P. Collins(International Breast Cancer Study Group), Alan S. Coates(International Breast Cancer Study Group), A. Gudgeon(International Breast Cancer Study Group), Karen N. Price(International Breast Cancer Study Group), Carl-Magnus Rudenstam(International Breast Cancer Study Group), Martin F. Fey(European Union), Hans-Jörg Senn(International Breast Cancer Study Group), F. Cavalli(European School of Oncology), Jürg Bernhard(International Breast Cancer Study Group), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Marco Bonetti(International Breast Cancer Study Group), H. Cortés-Funes(Centre Hospitalier René-Dubos)
Cited by 295
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k